Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Tumour response rate · people with metastatic colorectal cancer ‐ KRAS exon 2 WT
The intervention leads to higher tumour response rate (high certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Overall survival · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Tumour response rate · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status
The intervention probably leads to lower grade 3 to 4 neutropenia (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ KRAS exon 2 WT
The intervention probably leads to higher overall grade 3 to 4 toxicity (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Progression‐free survival · people with metastatic colorectal cancer
The intervention showed no clear difference in progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with metastatic colorectal cancer
The intervention showed no clear difference in overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Tumour response rate · people with metastatic colorectal cancer
The intervention probably leads to higher tumour response rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer
The intervention probably leads to higher overall grade 3 to 4 toxicity (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer
It is very uncertain whether the intervention changes grade 3 to 4 diarrhoea (very low certainty).
1 finding from 1 review